EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K / AKT signaling can be reversed by anlotinib

Yuan Gao iD, Yingfang Feng, Shaochuan Liu, Yan Zhang, Jing Wang, Tingting Qin iD, Peng Chen iD, Kai Li iD

Cancer Medicine · 2023-07 · 12 (14) · 15337-15349

DOI: 10.1002/cam4.6195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 23.06.2023. Verfasst von Yuan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the benefit with cancer immunotherapies in clinical implication, immunotherapeutic resistance occurred in many patients and the mechanism remains unknown. Increasing evidence has revealed that cell‐intrinsic programmed cell death ligand 1 (PD‐L1) may play a non‐negotiable part in immunotherapeutic resistance. Our present study aimed to elucidate the immune‐independent acquired resistance mechanism to PD‐L1 antibody. We found elevated PD‐L1 expression induced by PD‐L1 antibodies in cancer cell and vascular endothelial cells (VECs) with substantially acquired resistance to PD‐L1 antibodies. Moreover, proliferation of resistant cells was accelerated and the apoptosis was reduced in the absence of immune compared with parental cells. Subsequently, we confirmed that the activation of the PI3K/AKT pathway is involved in the upregulation of PD‐L1 expression. Finally, we found that low dose of anlotinib downregulated PD‐L1 expression only in VECs via inhibiting the PI3K/AKT pathway; however, the same effect was not observed in cancer cells. To sum up, our findings revealed that upregulation of PD‐L1 via activation of the PI3K/AKT signal pathway may promote acquired resistance to PD‐L1 antibodies in an immune‐independent manner. Significance These findings provide new mechanisms of immunotherapeutic resistance and effective evidence of anlotinib combined with immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesHumansB7-H1 AntigenUp-RegulationEndothelial CellsSignal TransductionAntibodiesCell Line, TumorIndolesQuinolines

Stichwörter der Autor:innen

PD-L1PI3K/AKTVECsanlotinibdrug resistancemelanoma

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesB7-H1 AntigenAntibodiesanlotinibIndolesQuinolines

Autor:innen und Institutionen

  • Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
  • Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.

ORCID-Profile: Yuan Gao, Tingting Qin, Peng Chen, Kai Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gao, Y., Feng, Y., Liu, S., Zhang, Y., Wang, J., Qin, T., Chen, P., & Li, K. (2023). Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K / AKT signaling can be reversed by anlotinib. Cancer Medicine, 12(14), 15337-15349. https://doi.org/10.1002/cam4.6195

Vancouver

Gao Y, Feng Y, Liu S, Zhang Y, Wang J, Qin T, et al. Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K / AKT signaling can be reversed by anlotinib. Cancer Medicine. 2023;12(14):15337-15349. doi:10.1002/cam4.6195

BibTeX
@article{Gao2023,
  author = {Gao, Yuan and Feng, Yingfang and Liu, Shaochuan and Zhang, Yan and Wang, Jing and Qin, Tingting and Chen, Peng and Li, Kai},
  title = {Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K / AKT signaling can be reversed by anlotinib},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {14},
  pages = {15337--15349},
  doi = {10.1002/cam4.6195}
}
Kostenlos starten →